2‑Deoxy‑D‑glucose enhances the anti‑cancer effects of idarubicin on idarubicin‑resistant P388 leukemia cells

  • Authors:
    • Taisuke Matsuo
    • Yumiko Konya
    • Eri Hirayama
    • Yasuyuki Sadzuka
  • View Affiliations

  • Published online on: May 13, 2020     https://doi.org/10.3892/ol.2020.11616
  • Pages: 962-966
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Cancer cells switch from mitochondrial oxidative phosphorylation to glycolysis, even in the presence of normal oxygen concentrations. Inhibition of the glycolytic pathway is therefore a critical strategy in cancer therapy. A non‑metabolic glucose analog, 2‑deoxy‑D‑glucose (2‑DG), has been the focus of research on glycolytic inhibitors for use in cancer treatment. The current study examined the anti‑cancer effects of 2‑DG on idarubicin (IDA)‑resistant P388 (P388/IDA) leukemia cells. P388/IDA cells were established following continuous exposure of IDA to P388 cells. Characterization of P388/IDA cells revealed increased lactate production and glucose consumption compared with P388 parent cells. The results of a cell viability assay determined that 2‑DG induces higher toxicity in P388/IDA cells compared with P388 cells. Although 2‑DG also exhibits endoplasmic reticulum (ER) stress‑inducing activity, the cytotoxic effect of the ER stress inducer, tunicamycin, on P388/IDA cells was lower than that of P388 cells. A combination of 2‑DG and IDA enhanced P388/IDA cell death compared with each agent alone. The results indicated that P388 cells activated glycolysis after acquiring IDA resistance and therefore, inhibition of the glycolytic pathway via 2‑DG might be a useful strategy for cancer therapy against IDA‑ resistant leukemia cells.

Related Articles

Journal Cover

July 2020
Volume 20 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Matsuo, T., Konya, Y., Hirayama, E., & Sadzuka, Y. (2020). 2‑Deoxy‑D‑glucose enhances the anti‑cancer effects of idarubicin on idarubicin‑resistant P388 leukemia cells. Oncology Letters, 20, 962-966. https://doi.org/10.3892/ol.2020.11616
MLA
Matsuo, T., Konya, Y., Hirayama, E., Sadzuka, Y."2‑Deoxy‑D‑glucose enhances the anti‑cancer effects of idarubicin on idarubicin‑resistant P388 leukemia cells". Oncology Letters 20.1 (2020): 962-966.
Chicago
Matsuo, T., Konya, Y., Hirayama, E., Sadzuka, Y."2‑Deoxy‑D‑glucose enhances the anti‑cancer effects of idarubicin on idarubicin‑resistant P388 leukemia cells". Oncology Letters 20, no. 1 (2020): 962-966. https://doi.org/10.3892/ol.2020.11616